

# BSIR IOUK ANNUAL MEETING 2023



# PROGRAMME

## 23<sup>RD</sup> & 24<sup>TH</sup> MAY 2023

## **HILTON AT THE AGEAS BOWL**

Botley Road, Southampton, SO30 3XH

# Improving the lives of patients and caregivers for over 50 years

Argon Medical is a global manufacturer of specialty medical products and offers a broad line of medical devices for Interventional Radiology, Vascular Surgery, Interventional Cardiology and Oncology.

The spirit of innovation thrives as we focus on improving the lives of caregivers and patients by delivering best-in-class medical device products, programs and services. For over 50 years, medical professionals worldwide have trusted us to deliver consistent clinical performance.



nargon-medical @ArgonMedical fargonmedical

argonmedical.eu.com 01283 538538 uksales@argonmedical.com

## BSIR IOUK ANNUAL MEETING 2023 DAY 1 - TUESDAY 23<sup>RD</sup> MAY

#### TIME SESSION & TALK TITLE

#### **SPEAKERS**

- 08:15-08:45 REGISTRATION & WELCOME COFFEE
- **09:00-10:30** HANDS ON WORKSHOP ON EXHIBITION FLOOR (for full details please see page 6)
- 10:45-10:00 WELCOME & INTRODUCTION

#### 11:00-12:30 LIVER: METASTATIC COLORECTAL DISEASE UPDATE

- Overview of mCRC treatment: Molecular Profiling and Guideline Changes
- Update on Surgical Strategies
- Ablation of Small Volume Disease: Current Status
- PVE/DVE/Functional Assessment: Current Status
- Tumour Board

#### 12:30-13:00 GUERBET LUNCHTIME SYMPOSIUM TACE YOURSELF SERIOUSLY

- Evidence based TACE procedures
- Getting INSPIRE'd by TACE standardisation

#### 12:30-13:30 LUNCH BREAK

#### 13:30-15:30 SARCOMA SPECTRUM & IO

- Understanding the Spectrum and where IO can Contribute
- Treatment of Desmoids and Desmoid Fibrosis
- Neuroanatomy and avoiding Neural Injury
- Systemic chemo and Radiotherapy options
- Paediatric Sarcomas
- Case Discussion

#### Dr Guy Hickson & Dr Nick Railton

Dr David Breen & Dr Sachin Modi

#### Dr Peter Kennedy & Dr Peter Littler

Dr Andrew Bateman Prof. John Primrose Prof. Martijn Meijrinck Dr Peter Littler Dr Peter Kennedy & Dr Peter Littler

#### Dr Praveen Peddu

Prof. Maxime Ronot Dr Ananth Krishnan

#### Dr Steve Bandula & Prof. Tze Wah

Dr Jack Jennings Prof. Afshin Gangi Prof. Matt Callstrom Dr Peter Simmonds Dr Prem Patel Dr Steve Bandula & Professor Tze Wah

## BSIR IOUK ANNUAL MEETING 2023 DAY 1 - TUESDAY 23<sup>RD</sup> MAY

#### TIME SESSION & TALK TITLE

#### 15:30–16:00 REFRESHMENT BREAK

#### 16:00-17:30 IO: NEW APPROACHES

- Electrochemotherapy
- Optimal Spine Ablation
- Injectable intra-Tumoural Therapies: Why?
- MR-guided Prostate Ablation: How and Why?
- IRE: Applications and Directions
- Round Table Discussion

#### 17:30–18:00 REFRESHMENT BREAK

#### 18:00-18:30 BOSTON SCIENTIFIC EVENING SYMPOSIUM The RCC Treatment Landscape: Present and Future Outlook

#### **SPEAKERS**

#### Dr Phil Haslam & Prof. Afshin Gangi

Dr Fred Deschamps Dr Jack Jennings Dr Joe Sacco Dr Alex King Prof. Martijn Meijrinck Dr Phil Haslam & Prof. Afshin Gangi

#### Prof. Tze Min Wah & Prof. Maxine Tran

## BSIR IOUK ANNUAL MEETING 2023 DAY 2 - WEDNESDAY 24<sup>TH</sup> MAY

#### TIME SESSION & TALK TITLE

#### 09:00-10:30 METASTATIC LUNG DISEASE: HOW?

- Case for Resection: When?
- Case for SABR: When?
- Case for Microwave Ablation: When and How?
- Case for Cryoablation: Solstice Study
- Case Panel

#### 10:30-11:00 REFRESHMENT BREAK

#### 11:00-13:00 LIVER: DECISIONS IN INTERMEDIATE STAGE HCC

- BCLC-B: Current place of Systemic Therapy
- BCLC-B: Case for TACE
- BCLC-B: Case for C-TACE
- BCLC-B: Current place of Ablation
- BCLC-B: Current place for TARE
- Tumour Board

#### 13:00-13:30 SIRTEX LUNCHTIME SYMPOSIUM One day SIRT: The Kings Experience

13:00-14:00 LUNCH BREAK

#### 14:00-14:15 POSTER PRESENTATION AWARD

- 14:15-15:45 METASTATIC MIDGUT NET DISEASE
  - Epidemiology and Overview
  - Role of TAE and Outcomes
  - PRRT: Efficacy and Directions
  - Surgery: indications and limits for debulking purposes Mr Tom Armstrong
  - Case Panel

#### 15:45-16:00 MEETING CLOSE

#### **SPEAKERS**

#### Dr Charles Peebles & Dr Ewan Anderson

Mr Edwin Woo Dr Andrew Bates Dr Steve Bandula Prof. Matt Callstrom Dr Charles Peebles & Dr Ewan Anderson

### Dr Kate Nash

#### & Dr David Breen

Prof. Tim Meyer Dr Tim Bryant Dr Praveen Peddu Dr David Breen Dr Sachin Modi Dr Kate Nash & Dr David Breen

#### Dr Nabil Kibriya

#### **Dr Nick Railton**

#### Dr Mike Bayne & Dr Brian Stedman

Dr Judith Cave Dr Brian Stedman Dr Amy Eccles Mr Tom Armstrong Dr Mike Bayne & Dr Brian Stedman

### BSIR IOUK ANNUAL MEETING 2023 HANDS ON/WORKSHOP PROGRAMME

#### INTRODUCTION

Dr Guy Hickson and Dr Nick Railton

#### LIVER ABLATION

Dr Alex King, Professor Tze Wah and Dr Peter Kennedy

#### RADIOEMBOLISATION

Dr Brian Stedman, Dr Sachin Modi and Dr Peter Littler

#### **RENAL ABLATION**

Dr David Breen and Dr Phil Haslam

COMPLEX BILIARY

Dr Pavan Najran and Dr Clare Bent

TACE

Dr Tim Bryant and Dr Praveen Peddu

### **BOSTON SCIENTIFIC SYMPOSIUM**

The RCC Treatment Landscape:

Present and Future Outlook

Please bring your smartphones for an interactive session



Tuesday 23rd May 6-6.30PM

Chaired by: Professor Tze Min Wah



Boston

Speaker: Professor Maxine Tran

IOUK 2023 - EVENING SYMPOSIUM WITH DRINKS

### **CASCINATION**



Automatic organ segmentation including risk structures An improved AblaSure® algorithm Interactive planning mode





750





CASCINATION

Visualize and confidently treat - Find out more at our booth

### **BSIR IOUK 2023 - FACULTY LIST**

**Dr David Breen** - University Hospital Southampton, Southampton Dr Sachin Modi - University Hospital Southampton, Southampton **Dr Guy Hickson** – Gloucestershire Hospitals NHS trust, Gloucestershire **Dr Nick Railton** – Mid Essex Hospitals NHS Trust, Essex Professor Tim Meyer - University College London Hospitals NHS foundation Trust, London Dr Peter Kennedy – Belfast Trust, Belfast **Dr Andrew Bateman** – University Hospital Southampton, Southampton **Professor John Primrose** – University Hospital Southampton, Southampton Professor Martijn Meijerinck - Amsterdam University Medical Centre, Amsterdam **Mr Edwin Woo** - University Hospital Southampton, Southampton **Dr Peter Littler** – Freeman Hospital, Newcastle **Dr Steve Bandula** – University College London, London **Professor Tze Wah** – Leeds Teaching Hospitals Trust, Leeds **Dr Jack Jennings** – St Louis Children's Hospital, Missouri **Professor Afshin Gangi** – University Hospital Strasbourg, France Professor Matt Callstrom - Mayo Clinic, Minnesota Dr Peter Simmonds - University Hospital Southampton, Southampton Dr Prem Patel - Great Ormond Street, London Dr Phil Haslam – Freeman Hospital, Newcastle **Dr Fred Deschamps** – The Institute Gustave Roussy, Paris

**Dr Alex King** – University Hospital Southampton, Southampton

Dr Charles Peebles - University Hospital Southampton, Southampton

Dr Kate Nash - University Hospital Southampton, Southampton

Dr Tim Bryant - University Hospital Southampton, Southampton

**Dr Mike Bayne** – University Hospitals Dorset NHS Trust, Dorset

Dr Brian Stedman - University Hospital Southampton, Southampton

Dr Judith Cave - University Hospital Southampton, Southampton

Mr Tom Armstrong - Royal Free London NHS Trust, London

Dr Andrew Bates - University Hospital Southampton, Southampton

Dr Amy Eccles - Imperial College Healthcare NHS Trust, London

Professor Maxime Ronot - Beaujon Hospital, Clichy, France

**Dr Joe Sacco** – Clatterbridge Hospital, Wirral University Teaching Hospitals NHS Foundation Trust, Birkenhead

Dr Ewan Anderson - Oxford University Hospitals NHS Trust, Oxford

Dr Ananth Krishnan - Manchester Royal Infirmary, Manchester

**Professor Maxine Tran** – Royal Free, London

Dr Nabil Kibriya - Kings College Hospital, London

### THANKS ALL THE FACULTY AND PARTICIPANTS FOR THEIR VALUED PRESENTATIONS.

These presentations will be available online after the event for delegates and members.

For information on BSIR IOUK Faculty please visit www.bsir.org/meetings/bsir-iouk-2023

SIRTeX SIRTeX

## The Advantages ONLY SIR-Spheres® provide



SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd. ©2023 Sirtex Medical Europe GmbH. APM-EMEA-002-03-23



At Terumo Interventional Systems, we constantly work to refine and perfect our products so that Interventional Radiologists can do more. That is why we support great thinking that pushes back the boundaries of our field. We are committed to innovation that embraces intricacies and complexities. Our exceptional tools, such as LifePearl Drug Eluting Beads, Quirem Suite Radioembolisation Spheres and Dosimetry, Occlusafe Advanced TACE, TATO Microwave Ablation and Progreat. These tools are supported with education programs: Terumo Europe (terumolearningedge.eu) including dedicated Interventional Oncology workshops, which empower physicians with the confidence they need to perform ever-more challenging procedures and spark progress. We look forward to meeting you at IOUK.



## **BSIR IOUK 2023 - ABSTRACTS**

**SPO03369** - The Scottish MUO Score for augmenting decision making in intervention for malignant ureteric obstruction – Oliver Llewellyn

**SPO03368** - A Retrospective Case Number Review for Image-Guided Thermal Ablation of Both Pulmonary Metastases and Primaries. 2006-2022 in a UK Tertiary Centre. - Peter McLoughlin

**SPO03367** - Liver vein deprivation to induce future liver remnant hypertrophy prior to major hepatectomy for primary and secondary liver cancer – a systematic review and meta-analysis. - Tymoteusz Turlejski

**SP003366** - Complications Associated with Percutaneous Transhepatic Cholangiography and biliary drainage: a single-centre retrospective analysis. -Nethmee Malla

SP003364 - Hepatic ablation in a tertiary referral centre - Mark Macmillan-John

**SP003362** - Does selective oesophageal stenting following endoscopic evaluation reduce stent migration? Aims – Paul Jenkins

**SPO03361** - The prognosticators to improve percutaneous transhepatic biliary drainage selection in obstructive biliary malignancies. – Keith Chan

**SPO03356** - Audit on effectiveness and technical success of the CT guided radiofrequency ablation of osteoid osteoma. - Sarthak Bahl

**SPO03355** - Ultrasound Guided Core Biopsy vs Fine Needle Aspiration Cytology in the Diagnosis of Parotid Neoplasia: An Up-to-Date Review. - Paulette Kumi

SP003354 - Oesophageal stenting - Time for a rethink? - Rahim Akram

### **BSIR IOUK 2023 - ABSTRACT CONTENT**

## SP003369 - The Scottish MUO Score for augmenting decision making in intervention for malignant ureteric obstruction.

Category: Interventional Oncology Author 1: Oliver Llewellyn

**Introduction:** Malignant ureteric obstruction (MUO) occurs in advanced malignancy but there is no standard approach to management. Renal decompression can be achieved with percutaneous nephrostomy (PCN) or ureteric stenting (US). These interventions may improve renal function, facilitating further oncological treatment, but come with quality-of-life implications.

**Methods:** Retrospective multicentre audit of patients who underwent PCN or US for MUO 2008-2020 across 6 Scottish healthboards. Patients were identified by OPERA (theatre) and RIS (radiology) codes. Primary outcomes were overall survival (OS) following decompression, and development of a scoring tool to predict 3month survival. Secondary outcomes were change in renal function 3months post-intervention, and receipt of further treatment. Cox and logistic regression were used to generate the Scottish MUO score. Missing variables were imputed. For validation, the entire cohort was split 70:30 into discovery:validation groups.

**Results:** In 905 patients, OS was poor with 26% mortality at 3months, and 42% at 6months. Increased age, potassium, WCC, CRP, and lower haemoglobin and bilateral hydronephrosis were associated with poorer OS. The Scottish MUO Score was developed and validated, available at:(https://webapps.igmm.ed.ac.uk/world/ research/muo\_calculator/). It compares favourably with other scores with higher AUC and specificity. 85% of patients had eGFR<60 prior to intervention. 50% of these had a >20% improvement in creatinine at 3months. 43% of patients received further oncological treatment following intervention.

**Conclusion:** This study demonstrates MUO as a marker of advanced disease. We developed the Scottish MUO score which is valid for predicting low overall survival. We hope its use will guide decision making around intervention.

#### SP003368 - A Retrospective Case Number Review for Image-Guided Thermal Ablation of Both Pulmonary Metastases and Primaries. 2006-2022 in a UK Tertiary Centre.

Category: Interventional Oncology Author 1: Peter McLoughlin Author 2: Peter Kennedy Author 3: Rohan Verma

**Aims:** Image-guided percutaneous thermal ablation is becoming more widespread in its application for both pulmonary metastases and primaries. Offering a further therapeutic technique to the arsenal of oncology treatment. This study aims to assess the pulmonary tumour ablation case numbers from 2006-2022 and review the case mix's histological makeup. This will give essential insight required for future workforce planning and the potential requirement for investment in interventional oncology services.

**Materials and Methods:** A retrospective study on patients treated from 2006-2022 inclusive. Data was collected from the PACS/RIS and entered into Excel. The total number of ablation procedures and the number of individual patients were collected for each tumour.

**Results:** 226 ablation procedures were carried out throughout the study period. On 179 individual patients. Colorectal pulmonary metastases were the most frequently ablated tumour making up 42% of the case mix. Followed by; Bronchial Carcinoma 28%, Sarcoma 13%, Renal Cell Carcinoma 7%, Other 10%. Annual cases increased from 4 in 2006 to 32 in 2022. The ratio of the number of ablations per patient for colorectal metastases was 1.42 compared with 1.02 for bronchial carcinoma. 1.3% of the total cases were repeat ablation procedures.

**Conclusion:** There has been a significant increase in demand for thermal ablation for pulmonary tumours, with colorectal metastases making up the largest component typically due to multiple lesions per patient. This suggests a requirement for significant future investment in interventional oncology services to meet this increasing demand, relevant not just to our own centre but to others throughout the UK.

# SP003367 - Liver vein deprivation to induce future liver remnant hypertrophy prior to major hepatectomy for primary and secondary liver cancer – a systematic review and meta-analysis.

Category: Interventional Oncology Author 1: Tymoteusz Turlejski Author 2: Yan-Lin Li Author 3: Tomas Urbonas Author 4: Alex Gordon-Weeks Author 5: Philip Boardman Author 6: Daniel Kearns Author 7: Andrew MacDonald **Aims:** Liver venous deprivation (LVD) is a novel technique to facilitate future liver remnant (FLR) growth ahead of planned hepatic resection. However, the clinical outcomes after LVD are poorly understood. This study aims to quantify the rates of tumour resectability and FLR hypertrophy after LVD through systematic review of the literature and meta-analysis.

**Materials and Methods:** PubMed, Embase and Cochrane Library were searched from 2000 to April 2023 using a pre-defined strategy consisting of synonyms of the LVD technique (in accordance to PRISMA guidelines). The following inclusion criteria were used: English language, peer-reviewed publication, sample size > 1, primary or secondary liver malignancy, study reporting resectability rate following LVD without simultaneous procedures to boost FLR growth. Of those, articles reporting %FLR hypertrophy compared to baseline were included in the second meta-analysis. The Newcastle-Ottawa Scale was used to assess study quality.

**Results:** The literature search yielded 165 articles. Inclusion criteria were met by 16 studies (376 patients), of which 13 reported %FLR hypertrophy (344 patients). Only one prospective (non-randomised) study was identified. The pooled resectability rate was 89.2% [confidence interval 84.9% - 93.5%]. The pooled %FLR hypertrophy was 64.8% [confidence interval: 52.8% - 74.8%]. The most common indication for LVD were liver metastases (61.8% of reported). Only 4 pre-operative deaths (0.8%) were reported. **Conclusion:** LVD offers promising FLR hypertrophy and favourable tumour resectability rate, which should be interpreted with caution due to the risk of bias in predominantly small, retrospective studies. Prospective, randomised trials (DRAGON, HYPER-LIVO1) will help to evaluate this further.

#### SP003366 - Complications Associated with Percutaneous Transhepatic Cholangiography and biliary drainage: a single-centre retrospective analysis.

Category: Interventional Oncology Author 1: Nethmee Malla Author 2: James Gordon-Smith

**Aim:** To evaluate 30-day mortality and complication rates following percutaneous transhepatic cholangiography and biliary drainage (PTBD) procedures, and to compare local numbers with published literature.

**Materials and methods:** Retrospective analysis of all adult (>18 years) patients who underwent PTBD within our health board was performed, during a period of 2 years (01/01/2019 – 31/01/2020). Primary objectives were development of infectious (sepsis not attributed to other causes, cholangitis, abscess, cholecystitis) and non-infectious (bile leakage, clinically significant haemorrhage) within one week post-biliary puncture, as well as 30-day mortality.

**Results:** A total of 132 patients underwent 137 separate biliary punctures during the study period. 74% of patients underwent PTBD for an underlying malignant aetiology and 26% underwent PTBD for a benign aetiology (ex: post-transplant hepaticojejunostomy stricture). 30-day mortality for patients with benign aetiologies

was 2.9%, and 19.4% for patients with a malignant aetiology. Overall 30-day mortality was 15.2%. The rate of post-biliary puncture pancreatitis was 7.3%. The rate of infectious complications was 11.0%, and non-infectious complications was 5.9%. **Conclusion:** Both non-infectious and infectious complications are common post-PTBD, however overall 30-day mortality and pancreatitis rates remain lower than numbers published in similar studies. There is an established practice amongst endoscopists of administering per rectal NSAIDS in the prevention of post-ERCP pancreatitis, and it would be interesting to consider extending this to our practice as well, as would administering routine antibiotic prophylaxis for the prevention of post-PTBD biliary sepsis. Future work could also involve the analysis of potential risk factors for complications.

#### SP003364 - Hepatic ablation in a tertiary referral centre

Category: Interventional Oncology Author 1: Mark Thomas Macmillan Author 2: James Gordon-Smith

**Aims:** Hepatic ablation is an established therapy for the treatment of hepatic tumours most commonly HCC and colorectal cancer metastases. Reported recurrence rates are variable for local recurrence rate, and disease-free survival. This study reports hepatic ablations carried out in a tertiary referral centre.

**Methods:** This audit was approved by the local Caldicott guardian. Retrospective analysis of hepatic ablations carried out in the interventional radiology department under ultrasound guidance at the Royal Infirmary between October 2017 and October 2020 were considered.

**Results:** 97 patients were included in this study, who underwent 113 ablations. 74 patients (76.2%) had HCC secondary to ALD most commonly, 31.1% of cases. A further 15 patients had metastatic colorectal cancer (15.5%). Median lesion size was 18mm (Range 8-37mm). Technical success was achieved in 96.9% of cases. 8 cases used fluoroscopic angiography and a further 8 cases used hydro-dissection. 89.2% of cases employed microwave ablation, the remainder using RFA. 2 cases of hepatic abscess occurred following ablation, 2 cases of bleeding requiring embolization and a case of pleural effusion requiring drainage occurred, overall significant complication rate of 5.2%. Median follow up was 2.82 years, during which 30.1% developed local recurrence and 43.0% developed nonlocal intrahepatic recurrence. 1 year disease free survival was 61.3%. **Conclusion:** The Edinburgh experience of hepatic ablation has demonstrated high technical success rate and low complication rate. Recurrence rates are commensurate with previously published data. Further analysis of this data set may unveil factors associated with reduced recurrence and improved survival.

## SP003362 - Does selective oesophageal stenting following endoscopic evaluation reduce stent migration?

Category: Interventional Oncology Author 1: Paul Jenkins Author 2: Andrew MacCormick Author 3: Robin Alridge Author 4: Bruce Michael Fox

**Aim:** Oesophageal malignancy is commonly diagnosed at a late oncological stage with dysphagia. Severe dysphagia may be treated with a covered stent however migration rates up to 23% are described with associated morbidity including obstruction and perforation. Assessment of the degree of obstruction may be made using ease of endoscope passage in addition to dysphagia scoring. The aim of this study is to establish whether the ease of passage of endoscope demonstrates low migration rates.

**Methods:** 15 year single operator retrospective review at a tertiary oesophageal cancer centre between 2006 and 2020 with a dysphagia score (Mellow&Pinkas) grade 3 or 4. Cases were identified on the radiological information system (RIS) and migration rates were assessed with follow up imaging.

**Results:** 299 patients were identified with a median age of 74.8 years (Range 44-97). 147 were stented at first assessment, although in 11 oesophageal stenting was performed despite the endoscope being able to traverse the lesion. 53/299 (26.5%) were not stented due to the ease of passage of the endoscope. 30/53 (56.6%) had no further intervention with 23/53 (43.4%) subsequently stented. Of the 136 that were stented in accordance with the established criteria, stent migration occurred in 8 cases (5.9%). The clinically relevant migration rate, defined as migration requiring further intervention, was only 1.5% overall (2/136). In the 11 that were stented despite not meeting the established criteria, 1 migrated. **Conclusion:** We demonstrate a low migration rate using ease of endoscope passage as a marker of suitability of stent insertion.

## SP003361 - The prognosticators to improve percutaneous transhepatic biliary drainage selection in obstructive biliary malignancies.

Category: Interventional Oncology Author 1: Keith Chan Author 2: Ganesh Vigneswaran Author 3: Sachin Modi Author 4: Drew Maclean Author 5: Brian Stedman Author 6: Tim Bryant Author 7: Ben Maher **Aim:** To identify prognosticators of first-time percutaneous transhepatic biliary drainage (PTBD) for obstructive malignant disease.

**Materials and Methods:** A single centre retrospective data analysis was performed in first-time malignant PTBDs and their respective survival outcomes between 2017-2021. Prospective preprocedural prognostic factors included age, underlying aetiology, serum haemoglobin and bilirubin levels. The data was subsequently analysed using Kaplan-Meier survival analysis and log rank test. Cox Proportional Hazards regression was also used for multivariate analysis.

**Results:** 156 patients were eligible. These included 62 pancreatic, 55 hilar cholangiocarcinoma, 19 ampullary/duodenal, and 20 non-hepatobiliary cancers. The median overall survival for the cohort was 136 days. The underlying aetiology significantly impacted median overall survival time. Median survival of nonhepatobiliary cancers was 53 days compared to cholangiocarcinoma survival of 347 days (p < 0.001). Median survival for pancreatic and duodenal/ampullary carcinomas were 120 and 105 days, respectively. On multivariate analysis, we found that in addition to aetiology, patients >70 years, preprocedural haemoglobin (<110 g/L) and bilirubin (>232 umol/L) were all independent prognosticators and were associated with significantly lower survival (HR 1.2, 1.8, 1.6 and 1.4 respectively, all p<0.05). **Conclusion:** There are significant differences in overall survival outcomes among patients with different malignant obstructive biliary aetiologies who undergo percutaneous transhepatic biliary drainage (PTBD). These differences highlight the heterogeneity of the PTBD cohort, despite common treatment pathways. These findings have the potential to improve the patient selection process, helping doctors identify which patients are most likely to benefit from PTBD and optimising their treatment plans accordingly.

## SP003356 - Audit on effectiveness and technical success of the CT guided radiofrequency ablation of osteoid osteoma.

Category: Interventional Oncology Author 1: Sarthak Bahl

**Aims:** Osteoid osteoma is a painful benign neoplastic bone disease affecting children/ young adults.Treatment historically involved surgical excision, although difficulty in lesion localization and need for dissection had its problems.Radiofrequency ablation(RFA) has been found to be a safe, fast, and reliable method of treating osteoid osteomas. We looked at the RFA for osteoid osteomas done at our university hospital retrospectively and compared it to literature.

**Method:** Data collected for patients who underwent radiofrequency ablation for osteoid osteoma(n=15). The details collected included age of the patient,size of the nidus,site of osteoid osteoma,WHO checklist followed, technical success,histological confirmation,relative contraindications,post-op complications,day of discharge,change in symptoms and any recurrence. Follow-up period varied from 6 months to 2 years.

**Results:** The age range for patients who underwent osteoid osteoma was 10-18 years. The site of osteoid osteoma was divided into typical sites(n=12) which included femur(n=7), tibia(n=4), distal radius(n=1) and atypical sites(n=3) which included Sacrum S1/2(n=2) and capitate(n=1). The size of nidus ranged from 2mm-1.7cm. There was techincal success in 14 out of 15 radiofrequency ablation procedures (93% technical success simiar to literature). One case of techinal failure was due to under-achieved temperature caused by machine fault. Out of 15 patients who underwent RFA, all had some pain relief following the procedure (100%). There were 6 cases of recurrence, 5 of which underwent second RFA and following that have been asymptomatic. **Conclusion:** Radiofrequency ablation convincingly remains a popular method for management of benign osteoid osteomas, given better lesion localisation, less postop complications, almost nil dissection and same day discharge. It has comparitively higher technical success and lower rate of recurrence compared to surgical excision for

osteoid oseomas.

## SP003355 - Ultrasound Guided Core Biopsy vs Fine Needle Aspiration Cytology in the Diagnosis of Parotid Neoplasia: An Up-to-Date Review.

Category: Interventional Oncology Author 1: Paulette Kumi

**Aims:** The authors performed a literature review to provide an update on current practice and outcomes of both Fine needle aspiration cytology (FNAC) and Ultrasound guided core biopsy.

**Materials and Methods:** A literature review of EMBASE, Medline, PubMed and Google Scholar was conducted. Regarding USCB, four systematic reviews and meta analyses were identified, alongside three other studies that were not included within these papers. Regarding FNAC, three systematic reviews and meta analyses were identified, alongside seven other studies, not included within these papers, using optimised FNAC in sample sizes of over fifty.

**Results:** USCB has higher sensitivity, specificity and lower non-diagnostic rates than optimised fine needle aspiration cytology (FNAC). It also has a significantly higher sensitivity for the detection of malignancy. Complications post-USCB are uncommon, with only one reported case of tumour seeding and no cases of permanent facial nerve dysfunction. The technique is less operator dependent than FNAC, with less variation in results between institutions.

**Conclusions:** USCB can be considered as the optimum tool of choice for diagnosis of parotid neoplasia. This would particularly be the case in centres utilising FNAC with high non-diagnostic rates or reduced diagnostic accuracy when compared to USCB published data, or in centres establishing a new service.

#### SP003354 - Oesophageal stenting - Time for a rethink?

Category: Interventional Oncology Author 1: Rahim Akram Author 2: Hans-Ulrich Laasch

**Aims:** Oesophageal stenting was considered a last resort for managing oesophageal occlusion from incurable oesophageal carcinoma. With advancing oncologic regimens, patient survival has dramatically increased from 3 months to 2 years. This presents an increasing challenge to stents and materials, but also requires a more involved approach of interventionalists. This case-series demonstrates the challenges presented by the change of landscape of oesophageal cancer treatment and aims to identify changes required in the philosophy of stenting.

**Methods & Materials:** Two of the longest-term survivors with oesophageal carcinoma who underwent multiple/repeat stent procedures were selected. SECTRA was used to identify the chronological events in which stent procedures occurred, using fluoroscopic studies. CT studies in between were also used to identify acute complications.

**Results** Case1: 9 stent procedures. Patient experienced stent: migration, folding, impaction into bowel requiring laparotomy, fracture and conglomerate formation. Stent conglomerate revealed extra stent deployed at a different trust which was poorly documented. Case 2: 4 stent procedures. Patient experienced mild dysphagia with multiple episodes of stent migration. Currently, interval scans demonstrate stable disease with minimal dysphagia-related symptoms. No stent in-situ.

#### **Conclusion:**

Recurrent dysphagia will inevitably occur. Hence, it is crucial that interventionists understand: 1) The correct characteristics and limitations of devices. 2) Patient anatomy and specific requirements for tailoring stents. 3) The need for re-intervention is expected, hence patients be actively followed up for stent function and maintenance. 4) Good communication and a multi-disciplinary team approach are paramount. 5) Not everyone will benefit from stenting.

## Guerbet | 🏭

# INTERVENTIONAL IMAGING

REDEFINED





Visit our website: interventional.guerbet.com





www.igeamedical.com



## Interventional Oncology Solutions



**ELRA** Temperature controlled intraductal biliary RFA system



#### Solero Simple . Speedy . Scalable The single applicator system with the ability to complete up to a 5cm ablation in 6 minutes\*

\*Ex bovine liver – actual clinical results in perfused tissues may differ



NanoKnife

The NanoKnife IRE system reimagines localised therapy through its unique mechanism of action, improving precision, expanding versatility and increasing preservation giving you the control to tailor treatments with confidence.



To contact us, please scan the QR code





## SAVE THE DATE

## **EMEA Workshops and Reference Sites 2023 Schedule**

Upcoming medical education reference site visits and workshops involving comprehensive clinical presentations and interactive live case observations



varian

Register now by scanning the QR code! For any inquires, feel free to contact Tara Djanani at tara.djanani@varian.com



#### **REFERENCE SITE VISITS AND WORKSHOPS**

DATES	COURSE TITLE	LOCATION
JUNE		
26th and 27th	Reference site visit: Renal cryoablation	Maasstad Ziekenhuis, Rotterdam, Netherlands
OCTOBER		
16th and 17th	Reference site visit: Renal cryoablation	Maasstad Ziekenhuis, Rotterdam, Netherlands
NOVEMBER		
23rd and 24th	Reference site visit: Renal cryoablation	TBD





Visit us to find out more about our work this year in Interventional Oncology.

We continue to support additional centres interventional needs with our CT-Navigation System, IMACTIS.

Further we have been lucky to be a part of the INJECTABLE 1 trial by supporting the use of our RFA system.

Here's to a successful IOUK!

Thanks from all of us at BVM Medical,

http://www.bvmmedical.com/products

BSIR IOUK WOULD LIKE TO THANK THE FOLLOWING SPONSORS FOR THEIR CONTINUED SUPPORT OF IOUK 2023









# CASCINATION



Guerbet |









To receive CPD or Certificate of Attendance please complete the evaluation tab on Meeting & Webinar section of bsir.org website



British Society of Interventional Radiology

#### For further information please contact:

British Society of Interventional Radiology (BSIR) 63 Lincoln's Inn Fields, London WC2A 3JW Tel: +44 (0)20 7406 5998 | Email: meeting@bsir.org

www.bsir.org

